Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telios

Executive Summary

Lilly is terminating its osteoporosis R&D collaboration with the San Diego biotech company. The January 1993 agreement allowed Lilly to opt out after two years, and "Lilly felt that its commitment to other, later-stage product candidates in this therapeutic area warranted a focusing of its resources," Telios says. Lilly's raloxifene is in late-stage development for osteoporosis. Telios had received $1.5 mil. in funding from Lilly for each of the past two years. Telios intends to find another partner for its osteoporosis research
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel